ArticleRespiration; international review of thoracic diseases2026
The Alteplase Dose Assessment for Pleural Infection Therapy (ADAPT) Study-3: Efficacy and Safety of 1 mg Alteplase as a Starting Intrapleural Dose.
Article in Respiration; international review of thoracic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIntrapleural tissue plasminogen activator/deoxyribonuclease (tPA/DNase) therapy has revolutionised management of pleural infection. However, the optimal tPA dose is still unknown. The Alteplase Dose Assessment for Pleural infection Therapy (ADAPT) study-3 aims to evaluate the efficacy and safety of a lower starting intrapleural dose of 1 mg tPA (with 5 mg DNase) for pleural infection.
methodsConsecutive patients with pleural infection who required intrapleural fibrinolytic therapy were treated with 1 mg tPA/5 mg DNase. Escalation of tPA doses were permitted at any time at the discretion of treating physicians.
resultsA total of 100 patients (22% female, mean age = 60.2) received a starting dose of intrapleural 1 mg tPA/5 mg DNase. Most (94%) patients were successfully treated and were discharged without needing surgery. Patients received a median of 5 [IQR = 3-6] doses of tPA/DNase and 6 mg of tPA [median, IQR = 3-8] in total. Treatment success was supported by improved pleural fluid drainage (from 238 mL pre-treatment to 2013 mL [IQR = 1,269-2,863] at 72 h, p < 0.0001), reduction in serum C-reactive protein levels (by 47.5% on day 5, p < 0.0001), and clearance in radiographic pleural opacities (from median 24% [IQR = 15-34] of hemithorax before tPA/DNase therapy to 10% [IQR = 7-15] 72 h after the first dose of tPA/DNase, p < 0.0001). In 28 (28%) patients, tPA dose was escalated due to minimal drainage and/or persistent sepsis; 26 were successfully treated and 2 required surgery. One (1%) patient experienced pleural bleed. Four patients with metastatic cancers were palliated during treatment for pleural infection and died.
conclusionA starting intrapleural regimen of 1 mg tPA/5 mg DNase, with dose escalation as necessary, appears to be safe and effective for pleural infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.